Category: InVivo Therapeutics Corp.
InVivo Therapeutics adds a 3rd clinical site to a feasibility study of its biodegradable implant to treat acute spinal cord injuries.
InVivo Therapeutics readies a 1-for-4 reverse stock split ahead of a planned listing on the NASDAQ stock exchange.
Ferolyn Powell, the former CEO of Evalve who led it to a $410 million acquisition by Abbott, is killed in a motorbike accident in Thailand.
Former Evalve CEO Ferolyn Powell, who led the MitraClip developer to a $410 million acquisition by Abbott (NYSE:ABT), died this month in a motorbike accident in northern Thailand, her family said yesterday.
, Cantel Medical Corp.
, Clayton Dubilier Rice
, InVivo Therapeutics Corp.
, JP Morgan Chase
, NxThera Inc.
, Spectranetics Corp.
, SurModics Inc.
, Urologix Inc.
, Abbott Laboratories
InVivo Therapeutics reports narrowed annual losses, due in part to changes in the market value of the company's derivative warrant liability.
(OTC:IVOB) reported a narrowed annual loss, due in part to changes in the market value of the company's derivative warrant liability.
Massachusetts-based InVivo Therapeutics looks to raise $12 million in a direct offering as it enrolls the 2nd patient in a feasibility trial for its neuro-spinal scaffold.
InVivo Therapeutics gets a green light to reopen enrollment in a clinical study of its neuro-spinal scaffold for treating acute spinal cord injuries.
The FDA approves an expedited enrollment plan for a 5-patient pivotal study testing InVivo Therapeutics' neuro-spinal scaffold devices in the treatment of severe spinal cord injuries.